Compare ALEMBIC with J.B.Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs J.B.CHEMICALS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC J.B.CHEMICALS ALEMBIC/
J.B.CHEMICALS
 
P/E (TTM) x 20.9 30.2 69.0% View Chart
P/BV x 0.8 6.7 11.7% View Chart
Dividend Yield % 0.3 1.0 27.2%  

Financials

 ALEMBIC   J.B.CHEMICALS
EQUITY SHARE DATA
    ALEMBIC
Mar-21
J.B.CHEMICALS
Mar-21
ALEMBIC/
J.B.CHEMICALS
5-Yr Chart
Click to enlarge
High Rs1231,318 9.3%   
Low Rs32443 7.2%   
Sales per share (Unadj.) Rs2.9264.3 1.1%  
Earnings per share (Unadj.) Rs0.558.0 0.9%  
Cash flow per share (Unadj.) Rs0.766.9 1.0%  
Dividends per share (Unadj.) Rs0.2016.50 1.2%  
Avg Dividend yield %0.31.9 13.8%  
Book value per share (Unadj.) Rs89.5234.2 38.2%  
Shares outstanding (eoy) m256.7877.28 332.3%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x27.03.3 811.3%   
Avg P/E ratio x143.515.2 946.2%  
P/CF ratio (eoy) x111.713.2 849.3%  
Price / Book Value ratio x0.93.8 23.0%  
Dividend payout %37.128.4 130.5%   
Avg Mkt Cap Rs m19,86868,043 29.2%   
No. of employees `000NANA-   
Total wages/salary Rs m2263,406 6.6%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m73520,425 3.6%  
Other income Rs m1091,166 9.4%   
Total revenues Rs m84421,591 3.9%   
Gross profit Rs m1045,562 1.9%  
Depreciation Rs m39687 5.7%   
Interest Rs m472 5.0%   
Profit before tax Rs m1705,969 2.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m321,484 2.2%   
Profit after tax Rs m1384,485 3.1%  
Gross profit margin %14.227.2 52.1%  
Effective tax rate %18.824.9 75.5%   
Net profit margin %18.822.0 85.7%  
BALANCE SHEET DATA
Current assets Rs m1,02118,939 5.4%   
Current liabilities Rs m5946,866 8.7%   
Net working cap to sales %58.159.1 98.2%  
Current ratio x1.72.8 62.3%  
Inventory Days Days10,191122 8,333.6%  
Debtors Days Days686695 98.6%  
Net fixed assets Rs m23,0696,786 340.0%   
Share capital Rs m514155 332.3%   
"Free" reserves Rs m22,45717,943 125.2%   
Net worth Rs m22,97018,097 126.9%   
Long term debt Rs m00-   
Total assets Rs m24,09025,725 93.6%  
Interest coverage x48.183.4 57.6%   
Debt to equity ratio x00-  
Sales to assets ratio x00.8 3.8%   
Return on assets %0.617.7 3.3%  
Return on equity %0.624.8 2.4%  
Return on capital %0.833.4 2.3%  
Exports to sales %1.50-   
Imports to sales %6.10-   
Exports (fob) Rs m11NA-   
Imports (cif) Rs m45NA-   
Fx inflow Rs m119,082 0.1%   
Fx outflow Rs m451,792 2.5%   
Net fx Rs m-347,290 -0.5%   
CASH FLOW
From Operations Rs m-223,148 -0.7%  
From Investments Rs m-347-2,307 15.1%  
From Financial Activity Rs m-154-874 17.6%  
Net Cashflow Rs m-523-33 1,594.9%  

Share Holding

Indian Promoters % 70.9 0.0 -  
Foreign collaborators % 0.0 54.0 -  
Indian inst/Mut Fund % 5.8 26.1 22.3%  
FIIs % 1.1 9.2 12.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 29.1 46.0 63.3%  
Shareholders   80,135 61,314 130.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 236 Points Lower, Nifty Falls Below 16,150; IT & FMCG Stocks Witness Selling(Closing)

Indian share markets ended on a negative note today as global cues remained weak.

Related Views on News

J B Chemicals & Pharma's Decent Performance Puts Stock in Focus (Views On News)

Aug 13, 2021

The company seeks to expand the market for prescription lozenges with new launches this year.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


May 24, 2022 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE ALEMBIC WITH

MARKET STATS